Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
16/04/2026 21:44
April 16 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O: ACURX PHARMACEUTICALS, INC. ANNOUNCES CLOSING OF UP TO $7.1 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES Source text: ID:nPn10HFr4a Further company coverage: ACXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program